A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-07-23
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 20); relationship: not assessed
severe
assessed
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 35); relationship: not assessed
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 46); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 61); relationship: not assessed
Data queries
No data queries.